Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07578649 | Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer | PHASE3 | NOT YET_RECRUITING | 600 | — | — | Oct 9, 2026 | Jan 30, 2031 | Jun 4, 2026 | 4 | United States |
PFS by BICR is defined as the time from the date of randomization to the date of first documented disease progression per RECIST v1.1 as assessed by BICR, or death due to any cause, whichever occurs first.
| Arm | Type | Description |
|---|---|---|
| PF-08634404 plus Chemotherapy | EXPERIMENTAL | PF-08634404 plus Chemotherapy, followed by PF-08634404 maintenance therapy |
| Pembrolizumab plus Chemotherapy | ACTIVE_COMPARATOR | Pembrolizumab plus Chemotherapy, followed by Pembrolizumab maintenance therapy |
| Name | Type | Description |
|---|---|---|
| PF-08634404 | BIOLOGICAL | Solution for IV infusion |
| Pembrolizumab | BIOLOGICAL | Solution for IV infusion |
| Standard of Care Chemotherapy | DRUG | Solution for IV infusion |
Inclusion Criteria: * Women ≥18 years of age who are confirmed not pregnant at screening. * Histologically or cytologically confirmed endometrial cancer that is recurrent or advanced; carcinosarcomas are eligible but pure sarcomas are excluded. * Newly diagnosed FIGO Stage III disease with measurab...